DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Follow-Up Questions
¿Cuál es el ratio P/E de Dexcom Inc (DXCM)?
El ratio P/E de Dexcom Inc es 43.738
¿Qué tal es el rendimiento del precio de la acción DXCM?
El precio actual de DXCM es de $61.01, ha decreased un 0.27% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Dexcom Inc?
Dexcom Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Dexcom Inc?
La capitalización bursátil actual de Dexcom Inc es $23.9B
¿Es Dexcom Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 30 analistas han realizado calificaciones de análisis para Dexcom Inc, incluyendo 15 fuerte compra, 15 compra, 5 mantener, 0 venta, y 15 fuerte venta
